Palisade Bio Statistics
Total Valuation
Palisade Bio has a market cap or net worth of $150.58 million. The enterprise value is $36.96 million.
Important Dates
The last earnings date was Tuesday, November 10, 2026, after market close.
| Earnings Date | Nov 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Palisade Bio has 179.28 million shares outstanding. The number of shares has increased by 4,252.89% in one year.
| Current Share Class | 179.28M |
| Shares Outstanding | 179.28M |
| Shares Change (YoY) | +4,252.89% |
| Shares Change (QoQ) | +0.31% |
| Owned by Insiders (%) | 2.20% |
| Owned by Institutions (%) | 80.42% |
| Float | 138.56M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 301.15 |
| Forward PS | n/a |
| PB Ratio | 1.30 |
| P/TBV Ratio | 1.34 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 73.92 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 20.16, with zero debt.
| Current Ratio | 20.16 |
| Quick Ratio | 19.50 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -16,042.33 |
Financial Efficiency
Return on equity (ROE) is -75.56% and return on invested capital (ROIC) is -51.92%.
| Return on Equity (ROE) | -75.56% |
| Return on Assets (ROA) | -69.63% |
| Return on Invested Capital (ROIC) | -51.92% |
| Return on Capital Employed (ROCE) | -42.70% |
| Weighted Average Cost of Capital (WACC) | 13.14% |
| Revenue Per Employee | $35,714 |
| Profits Per Employee | -$3.12M |
| Employee Count | 14 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -61.29% in the last 52 weeks. The beta is 1.62, so Palisade Bio's price volatility has been higher than the market average.
| Beta (5Y) | 1.62 |
| 52-Week Price Change | -61.29% |
| 50-Day Moving Average | 1.37 |
| 200-Day Moving Average | 1.81 |
| Relative Strength Index (RSI) | 24.56 |
| Average Volume (20 Days) | 4,065,281 |
Short Selling Information
The latest short interest is 29.29 million, so 16.34% of the outstanding shares have been sold short.
| Short Interest | 29.29M |
| Short Previous Month | 31.75M |
| Short % of Shares Out | 16.34% |
| Short % of Float | 21.14% |
| Short Ratio (days to cover) | 9.80 |
Income Statement
In the last 12 months, Palisade Bio had revenue of $500,000 and -$43.70 million in losses. Loss per share was -$0.21.
| Revenue | 500,000 |
| Gross Profit | 500,000 |
| Operating Income | -48.13M |
| Pretax Income | -43.70M |
| Net Income | -43.70M |
| EBITDA | -48.12M |
| EBIT | -48.13M |
| Loss Per Share | -$0.21 |
Full Income Statement Balance Sheet
The company has $113.61 million in cash and no debt, with a net cash position of $113.61 million or $0.63 per share.
| Cash & Cash Equivalents | 113.61M |
| Total Debt | n/a |
| Net Cash | 113.61M |
| Net Cash Per Share | $0.63 |
| Equity (Book Value) | 112.44M |
| Book Value Per Share | 0.64 |
| Working Capital | 111.65M |
Full Balance Sheet Cash Flow
| Operating Cash Flow | -26.40M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 2,250 |
| Net Borrowing | -211,000 |
| Free Cash Flow | -26.40M |
| FCF Per Share | -$0.15 |
Full Cash Flow Statement Margins
| Gross Margin | 100.00% |
| Operating Margin | -9,625.40% |
| Pretax Margin | -8,739.20% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Palisade Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -4,252.89% |
| Shareholder Yield | -4,252.89% |
| Earnings Yield | -24.81% |
| FCF Yield | -17.53% |
Analyst Forecast
The average price target for Palisade Bio is $8.70, which is 935.84% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $8.70 |
| Price Target Difference | 935.84% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
The last stock split was on April 8, 2024. It was a reverse split with a ratio of 1:15.
| Last Split Date | Apr 8, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:15 |
Scores
Palisade Bio has an Altman Z-Score of 27.34 and a Piotroski F-Score of 2.
| Altman Z-Score | 27.34 |
| Piotroski F-Score | 2 |